>> Login
>> New User Registration
September 9, 2010
Overview | Disclosure | Faculty | Agenda | Hotel Accommodations | Registration
Co-Chairs

Dr. Bunn
Paul A. Bunn, Jr., MD
James Dudley Chair in Cancer Research
Professor and Director
University of Colorado Cancer Center
Denver, CO
Executive Director
International Association for the Study of Lung Cancer
(IASLC)

Dr. Bunn
Roy S. Herbst, MD, PhD
Chief, Section of Thoracic Oncology
Professor of Medicine & Cancer Biology
Department of Thoracic / Head & Neck Medical Oncology
Co-Director, Phase I Clinical Trials Working Group
The University of Texas
M. D. Anderson Cancer Center
Houston, TX

Dr. Bunn
Corey J. Langer, MD
Director of Thoracic Oncology
University of Pennsylvania
Philadelphia, PA
Vice Chair of the Radiation Therapy Oncology Group
(RTOG)

Other Expert Faculty

Dr. Albain
Kathy S. Albain, M.D.
Professor of Medicine
Loyola University Chicago Stritch School of Medicine
Director, Thoracic Oncology Program
Director, Breast Clinical Research Program
Cardinal Bernardin Cancer Center
Maywood, IL

Gerold Bepler, MD, PhD
Professor of Medicine and Oncology
Division Chief and Program Leader
Thoracic Oncology
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL

Dr. Bonomi
Philip Bonomi, MD
Alice Pirie Wirtz Professor of Medical Oncology
Director, Division of Hematology-Oncology
Rush University Medical Center
Chicago, IL

David P. Carbone, MD, PhD
Harold L. Moses Chair in Cancer Research
Ingram Professor of Cancer Research
Director of Specialized Program of Research Excellence in Lung Cancer
Ingram-Vanderbilt Cancer Center
Nashville, TN

 


Walter J. Curran, MD, FACR
Professor and Chair
Department of Radiation Oncology
Emory School of Medicine Chief Medical Officer
Winship Cancer Institute
Atlanta, GA
Chairman, Radiation Therapy Oncology Group
(RTOG)

Martin J. Edelman, MD
Professor of Medicine
Director of Medical Thoracic Oncology
University of Maryland Greenebaum Cancer Center
Baltimore, MD

David R. Gandara, MD
Professor of Medicine Director, Thoracic Oncology Program Associate Director for Clinical Research,
UC Davis Cancer Center
Sacramento, CA
Chair, Lung Committee, Southwestern Oncology Group
(SWOG)

Richard J. Gralla, MD
Vice President, Cancer Services
Chief, Division of Hematology & Oncology
Monter Cancer Center
North Shore-LIJ Health System
Lake Success, NY

John V. Heymach, MD, PhD
Assistant Professor of Thoracic Head/Neck Medical Oncology
Assistant Professor of Cancer Biology
The University of Texas
M. D. Anderson Cancer Center
Houston, TX

Fred R. Hirsch, MD
Professor of Medicine and Pathology
University of Colorado Cancer Center
Denver, CO

David Jablons, MD
Section Chief, General Thoracic Surgery
Professor of Surgery
Division of Cardiothoracic Surgery
University of California, San Francisco
San Francisco, CA

Dr. Kim
Edward S. Kim, MD
Assistant Professor
Department of Thoracic/Head & Neck Cancer
The University of Texas
M. D. Anderson Cancer Center
Houston, TX

Mark G. Kris, MD
 Chief, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan-Kettering Cancer Center
New York, NY

Primo N. Lara, Jr., MD
 Professor of Medicine
Director, Clinical Trials Support Unit
UC Davis Cancer Center
Sacramento, CA

Thomas J. Lynch, MD
Chief, Division of Hematology and Oncology
Director, Center for Thoracic Cancer
Massachusetts General Hospital
Cancer Center
Boston, MA

Vincent A. Miller , MD
 Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, NY

Gordon Mills, MD, PhD
Chairman, Department of Molecular Therapeutics Professor of Medicine
University of Texas
M. D. Anderson Cancer Center
Houston, TX

John D. Minna, MD
Max L.Thomas Distinguished Chair in Molecular Pulmonary Oncology
Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research
Professor, Internal Medicine
Graduate School of Biomedical Sciences
UT Southwestern Medical Center
Dallas, TX

Jeffrey N. Myers, MD, PhD
Professor and Deputy Chair for Academic Programs
Director of Research for Head and Neck Surgery
The University of Texas
M. D. Anderson Cancer Center
Houston, TX

Joseph R. Nevins, PhD
Barbara Levine University Professor of Cancer Genomics
Duke University
Durham, NC

Dr. Patel
Jyoti D. Patel, MD
Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive
Cancer Center
Northwestern University
Chicago, IL

Dr. Salgia
Ravi Salgia, MD, PhD
Associate Professor of Medicine
Director, Thoracic Oncology Research Program
University of Chicago Medical Center
Chicago, IL

Alan B. Sandler, MD
Associate Professor of Cancer Research,
Lung Cancer
Ingram-Vanderbilt Cancer Center
Nashville, TN

Joan H. Schiller, MD
Professor & Division Chief,
Hematology-Oncology
Deputy Director, Harold C. Simmons Cancer Center
Andrea L. Simons Distinguished Chair in Cancer Research
UT Southwestern Medical Center
Dallas, TX
Chair, Lung Committee, Eastern Cooperative Oncology Group (ECOG)

David Sidransky, MD
Professor of Oncology,
Pathology and Cellular and Molecular Medicine
Director, Head and Neck Cancer Research
Johns Hopkins Medical Institutions
Baltimore, MD

George R. Simon, MD, FACP, FCCP
Associate Member
Department of Thoracic Oncology and Experimental Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL

Everett E. Vokes, MD
Director, Section of Hematology/Oncology
Deputy Director, Cancer Research Center
John E. Ultmann Professor of Medicine
Radiation and Cellular Oncology
The University of Chicago Medical Center
Chair, Lung Committee, Cancer and Leukemia Group B
(CALGB)

Ralph Zinner, MD
Associate Professor of Medicine
University of Texas
M. D. Anderson Cancer Center
Houston, TX
Tell a friend about this symposium Print the Agenda Email the Agenda

September 20-21, 2008 · The W Chicago City Center · Chicago, IL

A completely new concept in medical education for thoracic malignancies, developed to help clinicians improve their selection of the most appropriate targeted therapeutics and chemotherapeutics, and also help them to identify certain patient sub-populations of thoracic malignancies who may best respond to specific drug therapies
CO-CHAIRS

Paul A. Bunn, Jr., MD
James Dudley Chair in Cancer Research
Professor and Director
University of Colorado Cancer Center
Denver, CO
Executive Director
International Association for the Study of Lung Cancer
(IASLC)

Roy S. Herbst, MD, PhD
Chief, Section of Thoracic Oncology
Professor of Medicine & Cancer Biology
Department of Thoracic / Head & Neck Medical Oncology
Co-Director, Phase I Clinical Trials Working Group
The University of Texas, M. D. Anderson Cancer Center
Houston, TX

Corey J. Langer, MD
Director of Thoracic Oncology
University of Pennsylvania
Philadelphia, PA
Vice Chair of the Radiation Therapy Oncology Group
(RTOG)


ORGANIZING COMMITTEE


Paul A. Bunn, Jr., MD
James Dudley Chair in Cancer Research
Professor and Director
University of Colorado Cancer Center
Denver, CO
Executive Director,
International Association for the Study of Lung Cancer
(IASLC)

Roy S. Herbst, MD, PhD
Chief, Section of Thoracic Oncology
Professor of Medicine & Cancer Biology
Department of Thoracic / Head & Neck Medical Oncology
Co-Director, Phase I Clinical Trials Working Group
The University of Texas, M. D. Anderson Cancer Center
Houston, TX

David Jablons, MD
Section Chief, General Thoracic Surgery
Professor of Surgery
Division of Cardiothoracic Surgery
University of California, San Francisco
San Francisco, CA

Corey J. Langer, MD
Director of Thoracic Oncology
University of Pennsylvania
Philadelphia, PA Vice Chair,
Radiation Therapy Oncology Group
(RTOG)

Joan H. Schiller, MD
Professor & Division Chief,
Hematology/Oncology
Deputy Director, Harold C. Simmons Comprehensive Cancer Center
Andrea L. Simmons Distinguished Chair in Cancer Research
UT Southwestern Medical Center
Dallas, TX
Chair, Lung Committee, Eastern Cooperative Oncology Group
(ECOG)

Everett E. Vokes, MD
Director, Section of Hematology/Oncology
Deputy Director, Cancer Research Center
John E. Ultmann Professor of Medicine
Radiation and Cellular Oncology
The University of Chicago Medical Center
Chair, Lung Committee, Cancer and Leukemia Group B
(CALGB)
   
•
 Educational Statement of Need
•
 Overview
•
 Disclosure
•
 Target Audience
•
 Learning Objectives
•
 CME Credit Information
•
 Methods of Participation
•
 Agenda
•
 Faculty
•
 Educational Grant Sponsorship Opportunities
•
 Hotel: Chicago W
•
 Registration
   
Agenda Back to Top
>
First Annual Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
September 19, 2008 - Friday
5:00PM – 9:00PM Early Registration second floor lobby
September 20, 2008 - Saturday
7:00AM – 8:00AM Buffet Breakfast second floor
7:00AM – 8:00AM Registration (continued) second floor lobby
Session 1: Introductions and Overview - P. Bunn
8:00AM – 8:20AM The rationale for personalized therapies for lung cancer and head & neck cancer  R. Herbst
Session 2: The Key Science, Biology and Genetics Involved with Personalizing Therapies for Thoracic Malignancies - Chair: J. Minna
8:20AM – 8:40AM The role of gene signatures for personalizing therapies for lung cancer  J. Nevins
8:40AM – 9:00AM The role of gene signatures in the prediction of therapeutic response of personalized therapies for lung cancer  J. Minna
9:00AM – 9:20AM The role of gene signatures in the prognosis and prediction of therapeutic response of personalized therapies for head and neck cancer  E. Kim
9:20AM – 9:40AM ERCC-1 and RRM-1: Survival- determining genes in lung cancer  G. Simon
9:40AM – 10:00AM BREAK  
10:00AM – 10:20AM Genomic predictors for clinical outcomes in resectable patients with lung cancer and head & neck cancer  D. Jablons
10:20AM – 10:40AM The role of proteomics and reverse phase arrays in personalizing therapies for thoracic malignancies G. Mills
10:40AM – 11:00AM “Point-Counterpoint #1:” All patients diagnosed with lung cancer should have their tumors profiled for genetic markers. Pro and Con. Audience Votes. J. Nevins vs. D. Jablons and Audience Voting
11:00AM– 11:30AM Question & Answer Session and Panel Discussion with faculty and audience
Faculty and Audience
11:30AM – 12:30PM LUNCH with the Professors: Each of today’s faculty members will be assigned a separate lunch table so the symposium audience can further interact with the faculty member on his/her presentation topic. Faculty and Audience
Session 3: Personalizing CHEMOTHERAPY for Lung Cancer and Head & Neck Cancer - D. Gandara

12:30PM-
12:50PM

 The role of molecular biomarkers for determining sensitivity and resistance to microtubule agents for lung cancer and head & neck cancer  D. Gandara
12:50PM – 1:10PM The role of molecular biomarkers, e.g., ERCC-1 for determining sensitivity and resistance to platinum therapies for lung cancer and head & neck cancer G. Simon
1:10PM – 1:30PM Predicting clinical response to combination chemotherapy with multi-targeted anti-folates in sub-populations of Non-small cell lung cancer  R. Zinner
1:30PM – 1:50PM Pharmacogenetic differences among lung cancer patient populations: implications for personalized therapy  P. Lara
1:50PM – 2:10PM Personalizing the role of taxanes and platinum compounds for the treatment of head & neck cancer  J. Myers
2:10PM – 2:30PM What is the role of RR –1 as a molecular biomarker for predicting response to anti-metabolites?  G. Bepler
2:30PM – 2:50PM Point-Counterpoint #2:” Tumor genetic mutations are critical for determining the choice of chemotherapy. Pro and Con. Audience Votes.
G. Simon vs. P. Lara and Audience Voting
2:50PM – 3:10PM
Case Study #1 and Q & A Interactive Panel Discussion #1 : What are the State of the Art First and Second Line Chemo-Based Therapies? And what current and potential future biomarkeres can be used to help clinicians devise personalized therapies? Audience response system handsets will be used to poll the participants.		 R. Salgia, Audience, and This Session's Faculty
3:10PM – 3:25PM Question & Answer Session and Panel Discussion with faculty and audience
Faculty and Audience
3:25PM – 3:40PM BREAK  
Session 4: Personalizing ANTI-EGFR THERAPY for Lung Cancer and Head & Neck Cancer - Chair: T. Lynch
3:40PM – 4:00PM EGFR mutations and their role in predicting sensitivity and resistance to anti-EGFR therapy for lung cancer and head & neck cancer  T. Lynch
4:00PM – 4:20PM The role of FISH and IHC in predicting patient response to anti-EGFR therapy for lung cancer and head & neck cancer  F. Hirsch
4:20PM – 4:40PM The role of Kras mutation testing in lung cancer and head & neck cancer  M. Kris
4:40PM – 5:00PM The role of proteomics in patient selection of anti-EGFR therapies for lung cancer and head & neck cancer
 D. Carbone

5:00PM – 5:20PM

 Are molecular biomarkers effective predicting anti-EGFR therapies in combinations with novel agents directed against other targets and pathways?  V. Miller
5:20PM – 5:40PM “Point-Counterpoint #3:” EGFR small molecules versus EGFR antibodies: which are more valuable? Pro and Con. Audience Votes.
V. Miller vs. T. Lynch and Audience Voting

5:40PM – 6:00PM
Case Study #2 and Q & A Interactive Panel Discussion #2 : What are the State of the Art First and Second Line anti-EGF-Based Therapies? And what current and potential future biomarkeres can be used to help clinicians devise personalized therapies? Audience response system handsets will be used to poll the participants.		 K. Albain, Audience, and This Session's Faculty
6:00PM-6:15PM Question & Answer Session and Panel Discussion with faculty and audience
Faculty and Audience
6:15PM DINNER "On Your Own"  
September 21, 2008 – Sunday
Session 5: Personalizing ANTI-ANGIOGENIC THERAPY for Lung Cancer and Head & Neck Cancer - Co-Chairs: E. Vokes and J. Schiller
7:30AM – 7:50AM Personalizing the use of anti-VEGF monoclonal antibodies for the treatment of lung cancer and head and neck cancer  A. Sandler
7:50AM – 8:10AM Personalizing the clinical applications of small molecule, tyrosine kinase inhibitors for the treatment of lung cancer and head and neck cancer  J. Schiller
8:10AM – 8:30AM Multiple-targeted tyrosine kinase inhibitors: can their usage be personalized for the treatment of lung cancer and head and neck cancer?  T. Lynch
8:30AM – 8:50AM The role of predictive molecular biomarkers in personalizing therapies targeting VEGF for lung cancer and head and neck cancer  J. Heymach
8:50AM – 9:10AM “Point-Counterpoint #4:” The best target for inhibiting angiogenesis in lung cancer is the VEGF ligand, versus the best target is the receptor. Audience Votes. A. Sandler vs. J. Heymach and Audience Voting
9:10AM – 9:30AM Case Study #3 and Q & A Interactive Panel Discussion #3 : What are the State of the Art First and Second Line Anti-Angiogenic-Based Therapies? And what current and potential future biomarkeres can be used to help clinicians devise personalized therapies? Audience response system handsets will be used to poll the participants. J. Patel, Audience, and This Session's Faculty
9:30AM – 9:50AM BREAK  
Session 6: Radiation Therapy in Combination with Novel Targeted Therapies for Lung Cancer and Head & Neck Cancer - Chair: W. Curran
9:50AM – 10:10AM Personalizing radiation therapy with anti-EGFR therapies  C. Langer
10:10AM – 10:30AM Personalizing radiation therapy with anti-angiogenic therapies  W. Curran
10:30AM – 10:50AM Case Studies #4 and #5 and Q & A Interactive Panel Discussion with faculty and audience using the audience response system handsets Faculty and Audience
Session 7: Additional Targets, Pathways and Issues for Personalizing Therapies for Thoracic Malignancies - Chair: P. Bunn
10:50AM – 11:10PM The role of patient enrichment trials, using patient responses, to help determine who receives maintenance therapy  E. Vokes
11:10PM – 11:30PM Personalizing therapy for lung cancer patients utilizing Cox 2 inhibitors M. Edelman  
11:30PM – 11:50PM Are newer pathways and targets such as IGFR-1, aurora kinases and others helping us further develop personalized therapies for thoracic malignancies?  P. Bunn
11:50AM – 1:00PM LUNCH with the Professors: Each of today’s faculty members will be assigned a separate lunch table so the symposium audience can further interact with the faculty member on his/her presentation topic. Faculty and Audience
1:00PM-1:20PM Is there a role for personalizing therapies for Small Cell Lung Cancer?  A. Sandler
1:20PM-1:40PM Targeting anti-emetic regimens and doses for lung cancer therapies  R. Gralla
1:40PM – 2:00PM How do we incorporate personalized therapies for lung cancer and head and neck cancer into routine clinical practice?  D. Sidransky
2:00PM-2:20PM “Point-Counterpoint #5:” The majority of therapies for treating lung cancer will be personalized with molecular biomarkers by the year 2015. Pro and Con. P. Bunn vs. R. Gralla
2:20PM-2:40PM Case Study #6 and Q & A Interactive Panel Discussion #6: What are Some Emerging Therapies? And what current and potential future biomarkeres can be used to help clinicians devise personalized therapies? Audience response system handsets will be used to poll the participants. P. Bonomi, Audience, and This Session's Faculty
2:40PM-3:00PM What are the most promising new targets for personalizing the treatment of thoracic malignancies? A final, interactive question and answer session with the audience. R. Herbst, Faculty and Audience
3:00PM-3:15PM Question & Answer Session and Panel Discussion with faculty and audience
Faculty and Audience
3:15PM ADJOURN  
Educational Grants

Sincere appreciation is extended to the following companies for their generous support of this educational meeting: Genentech BioOncology, OSI Oncology, Lilly, Bristol-Myers Squibb, ImClone Systems Incorporated, sanofi-aventis, Biogen Idec, Poniard Pharmaceuticals, OSI Pharmaceuticals



























© 2010 Oncology Learning Center
1415 Legacy Drive, Suite 250 • Frisco, TX 75034 • Registration Phone: 214.269.2014 • Fax: 214.866.0311
Contact Us
Disclaimer: The material published on the Oncology Learning Center Web site reflect the opinions and expertise of the authors and/or reviewers of the material, and not the opinions of the Oncology Learning Center, the CME provider, or the pharmaceutical companies providing educational grants. The materials may address uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Before using any therapeutic approaches reviewed in this material, a qualified medical or surgical oncologist, or hematologist should be consulted. Readers of this content should verify all information and data before treating patients or using any drugs or therapies described in any Oncology Learning Center materials. Click here for our Privacy Policy.